Jasper reports 89% complete response in single-dose CSU cohorts, but drug lot issue delays Phase 2b to mid-2026

Jasper Therapeutics, Inc.

8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).
8 of 11 (73%) in 180mg Q8W open-label extension achieved complete response at week 12.
Results from 240mg Q8W and 240mg→180mg Q8W cohorts confounded by drug product lot issue affecting 10 of 13 patients.
ETESIAN asthma study halted due to same lot issue; SCID development stopped; cost cutting and potential restructuring.
Additional BEACON data expected Q4 2025; Phase 2b CSU study start delayed to mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.